Without therapeutic drug monitoring, there is no personalized cancer care

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 3, 2013, Pages 228-230

  Beumer, J H ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; METHOTREXATE; PACLITAXEL; SUNITINIB;

CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; DRUG EXPOSURE; DRUG INDUSTRY; DRUG MONITORING; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NOTE; PATIENT ADVOCACY; PERSONALIZED MEDICINE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84874148548     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.243     Document Type: Note

References (5)

1. de Jonge, M.E., Huitema, A.D., Schellens, J.H., Rodenhuis, S. & Beijnen, J.H. Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review. Clin. Pharmacokinet. 44, 147-173 (2005
2. Felici, A., Verweij, J. & Sparreboom, A. Dosing strategies for anticancer drugs: The good, the bad and body-surface area. Eur. J. Cancer 38, 1677-1684 (2002
3. Gao, B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M. & Gurney, H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol. 30, 4017-4025 (2012
4. Saleem, M., Dimeski, G., Kirkpatrick, C.M., Taylor, P.J. & Martin, J.H. Target concentration intervention in oncology: where are we at? Ther. Drug Monit. 34, 257-265 (2012
5. Dienstmann, R., Brana, I., Rodon, J. & Tabernero, J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16, 1729-1740